Countries around the world have legalized cannabis. Could psychedelics be next?
Global sales of antidepressant drugs are expected to exceed $20 billion by 2030.
Now, some investors are betting that psychedelic therapies can grab a share of that enormous market.
Due to their mind-bending qualities, substances like psilocybin, ketamine, LSD and MDMA remain illegal in most of the world.
That may help explain why markets are showing strong doubts about the industry.
A CNBC examination of seven psychedelic stocks that trade in the United States found that most of them are close to their 52-week lows as of mid-February, with some more than 80% lower than their 52-week highs.
But venture firms that invest in the new industry are standing by the drugs.
Watch the full report: https://youtu.be/A8SSpMAY5P4
#CNBC #Shorts
—–
Subscribe: http://cnb.cx/2wuoARM
CNBC International TV: https://cnb.cx/2NGytpz
Facebook:
https://www.facebook.com/cnbcinternational
Instagram:
https://www.instagram.com/cnbcinternational/
Twitter:
https://twitter.com/CNBCi
source